MARCO, LAYN, and IL10RB were linked to reduced PRAD risk, while C1QA, TXNDC15, IGFBP3, TNFRSF10C, TRIM5, JAM3, RNF43, PPP1R14A, SPINT2, and LGALS4 were associated with increased risk (Figure 2, Table S2). Here, LGALS4 is linked to prostate adenocarcinoma.